Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightBulgular: Hastaların 102’si (%34) naif hasta, 198’i (%66) tedavi deneyimliydi.
📌 3 Maddede Bu Makale
Özet
Amaç: Kronik hepatit C (KHC) tedavisinde direkt etkili antiviraller ile çok yüksek kalıcı virolojik yanıt (KVY) oranları elde edilmiştir. Bu çalışmada, hastalarda ledipasvir + sofosbuvir (Led + Sof), Sof, paritaprevir/ritonavir/ombitasvir + dasabuvir (PrOD) ve PrO içeren tedavilerin etkinliğinin ve güvenilirliğinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya KHC’li Led + Sof, Sof, PrOD veya PrO tedavisi alan 300 hasta alındı. Bulgular: Hastaların 102’si (%34) naif hasta, 198’i (%66) tedavi deneyimliydi. Hastaların 70’inde (%23,3) siroz mevcuttu. Hastaların 35’i (%11,7) genotip 1a, 261’i (%87) genotip 1b, 1’i (%0,3) genotip 2a, 2’si (%0,7) 3a ve 1’i (%0,3) genotip 4a olarak saptandı. Led + Sof ± ribavirin (R) alan hastalarda KVY oranı %98 saptanırken, PrOD ± R alan hastalarda %100 saptandı. Siroz, KVY’yi etkileyen tek faktör olarak saptandı. PrOD veya PrOD+R kullanan hastaların 60’ında (%40,5), Led + Sof veya Led + Sof + R kullanan hastaların 68’inde (%44,7) herhangi bir advers olay görüldü. Sonuç: KHC hastalarında, PrOD ve Led + Sof tedavileri, etkin ve güvenilir tedaviler olup, umut vadetmektedir.
Abstract
Objectives: In the treatment of chronic hepatitis C (CHC), very high rates of sustained virological response (SVR) have been obtained with direct-acting antivirals. In this study, we aimed to evaluate the efficacy and safety of therapies containing ledipasvir + sofosbuvir (Led + Sof), Sof, paritaprevir/ritonavir/ombitasvir + dasabuvir (PrOD) and PrO. Materials and Methods: Three hundred patients with CHC, who received Led + Sof, Sof, PrOD or PrO treatment were included in the study. Results: One hundred two (34%) of the patients were treatmentnaive patients and 198 (66%) had undergone treatment. Cirrhosis was present in 70 (23.3%) of the patients. Thirty-five (11.7%) of the patients were with genotype 1a, 261 (87%) were with genotype 1b, 1 (0.3%) was with genotype 2a, 2 (0.7%) were with 3a and 1 (0.3%) was with genotype 4a. While the rate of SVR was 98% in patients receiving Led +Sof ± ribavirin (R), it was 100% in patients receiving PrOD ± R. Cirrhosis was found to be the only factor affecting SVR. An adverse event was observed in 60 (40.5%) of patients using PrOD or PrOD + R, and in 68 (44.7%) of those using Led + Sof or Led + Sof + R. Conclusion: In CHC patients, PrOD and Led + Sof treatments are effective and reliable treatments and shows promise.